A synergistic reduction of melanoma cell proliferation and induction of cell death with combined mTOR and MAPK pathway inhibition was already reported (Gopal et al., 2010; Lasithiotakis et al., 2008; Molhoek, Brautigan & Slingluff, 2005), suggesting that this combined inhibitory therapy may benefit patients with BRAF mutant melanomas. This evidence concerns the gene MTOR and melanoma.